✨ Free AI Report
Revvity, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Revvity, Inc.
Company Research

Revvity, Inc.: Business Overview, Financials & Competitive Analysis

Revvity, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Well-positioned translational life sciences platform with strong diagnostics revenue stream; attractive consolidation target given recent operational efficiency improvements and strategic rebranding. With a market capitalization of $11.8B and trailing twelve month revenue of $2.86B, Revvity demonstrates solid financial performance. The company benefits from a broad customer base across pharma, diagnostics.

What is Revvity, Inc.'s industry? Revvity, Inc. (revvity.com) operates in Life Sciences and Diagnostics. AskCyborg classifies Revvity, Inc. under Life Sciences and Diagnostics in its company registry.

Revvity is an American company in the life sciences and diagnostics business focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy o...

7/ 10Strong

Cyborg Score thesis

Well-positioned translational life sciences platform with strong diagnostics revenue stream; attractive consolidation target...

Read the full analyst-debate transcript →
Industry Life Sciences and Diagnostics
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Revvity, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Revvity, Inc.

AskCyborg analysts argue the bull and bear cases for Revvity, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Revvity, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Revvity, Inc. Overview

Pro stress-test →

Revvity is an American company in the life sciences and diagnostics business focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health.

Strategic Profile

Pro stress-test →

The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023, marking a transformation aimed at strengthening its market position as a translational solutions provider. Revvity serves pharmaceutical and biotech, clinical labs, academia, and governments worldwide.

Competitive Landscape

Pro stress-test →

In life sciences, Revvity competes with Thermo Fisher Scientific, Agilent Technologies, and Danaher Corporation in analytical instrumentation, imaging systems, and laboratory automation. In diagnostics, the company faces competition from Abbott Laboratories, Roche Holding, and Siemens Healthineers in newborn screening and prenatal testing.

Industry Context

Revvity, Inc. operates in Life Sciences and Diagnostics.

Key facts

Founded: 1937 · Headquarters: Waltham, Massachusetts · Revenue: $2.86B · Market cap: $11.8B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Revvity, Inc..

  • Q4 2025 earnings beat analyst expectations, with analysts boosting forecasts following the results
  • Recent acquisition of ACD/Labs completed in November 2025 demonstrates continued strategic portfolio expansion
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Q4 2025 earnings beat expectations with analyst forecast upgrades
  • Nov 2025Acquisition of ACD/Labs to expand software and data management capabilities
  • +1 moreTrack every material event for Revvity, Inc. as it happens. Explore monitoring →
Get alerted when Revvity, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Thermo Fisher ScientificAnalytical instrumentation and research tools→Agilent TechnologiesLife sciences and diagnostics instrumentation→Danaher CorporationLaboratory automation and detection technologies→Abbott DiagnosticsNewborn screening and prenatal diagnostics→Roche DiagnosticsIn vitro diagnostics and testing solutions→

Compare Revvity, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Revvity, Inc. operates in Life Sciences and Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse Life Sciences and Diagnostics research →
NEW · MCP server

Ask your AI assistant about Revvity, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Revvity, Inc. and its top competitor on Cyborg Score”
“What did Revvity, Inc. do this quarter?”
“Is Revvity, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Revvity, Inc. do?+
Revvity is an American company in the life sciences and diagnostics business focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy o...
What is Revvity, Inc.'s Cyborg Score?+
Revvity, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Revvity, Inc.'s main competitors?+
Named competitors include Thermo Fisher Scientific, Agilent Technologies, Danaher Corporation, Abbott Diagnostics. The full competitive landscape is in the AskCyborg report.
How can I get the full Revvity, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Revvity, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Revvity, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Life Sciences and Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Revvity, Inc.8Danaher Corporation